Results 181 to 190 of about 659,948 (302)

Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7‐Year Prospective Matched Cohort Study

Movement Disorders, EarlyView.
Abstract Background Although clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear.
Li Zhou, Yaping Liu, Bei Huang, Jing Wang, Shi Tang, Yuhua Yang, Siyi Gong, Steven W.H. Chau, Joey W.Y. Chan, Mandy W.M. Yu, Jessie C.C. Tsang, Shirley Xin Li, Siu Ping Lam, Vincent C.T. Mok, Karen K.Y. Ma, Anne Y.Y. Chan, Jihui Zhang, Yun Kwok Wing   +17 more
wiley   +1 more source

Phosphorylated Alpha-Synuclein and Carboxymethyllysine in the Epidermis of Type 2 Diabetes Patients: Preliminary Observations. [PDF]

Biomedicines
Kordas B, Matuszewski W, Modzelewski R, Juranek J.   +3 more
europepmc   +1 more source

Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases

Movement Disorders, EarlyView.
Abstract Background Despite widespread cortical involvement in Lewy body diseases, conventional gray matter magnetic resonance imaging (MRI) shows limited sensitivity. Diffusion‐weighted MRI‐derived microstructural measures have shown utility in Alzheimer's disease, but their application across the Lewy body disease spectrum remains limited ...
Angeliki Zarkali, Ivelina Dobreva, Naomi Hannaway, Rohan Bhome, George E.C. Thomas, Steffani Carrera, Amanda J. Heslegrave, Elena Veleva, Henrik Zetterberg, Rimona S. Weil   +9 more
wiley   +1 more source

Single-molecule detection methods to study alpha-synuclein aggregation in postmortem Parkinson's disease brains. [PDF]

Cell Rep Methods
Fertan E, Danial JSH, Neame S, Lam JYL, Cotton MW, Burke M, Xia Z, Wu Y, Powney B, Imaizumi Y, Quaegebeur A, Meisl G, Staddon J, Klenerman D.   +13 more
europepmc   +1 more source

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham‐Controlled Trial

Movement Disorders, EarlyView.
Abstract Background Ultrasound‐based neuromodulation, capable of reaching deep brain areas with high precision, represents cutting‐edge technology in non‐invasive brain stimulation and is investigated as a novel treatment for neurological and psychiatric disorders, including Parkinson's disease (PD).
Eva Matt, Nina Plischek, Michael Mitterwallner, Sonja Radjenovic, Alexandra Weber, Alina Domitner, Gregor Dörl, Anna Zettl, Sarah Osou, Anna Leitgeb, Agnes Santer, Viktoria Winkler, Julia Mandelburger, Heidemarie Zach, Roland Beisteiner   +14 more
wiley   +1 more source

Tonsillar Alpha-Synuclein Accumulation on Parkinson's Disease. [PDF]

Noro Psikiyatr Ars
Sarıkaya C, Çalışkan S, Özdemir Ö, İşeri M, İşeri P.   +4 more
europepmc   +1 more source

Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...
Konstantin Senkevich, Sitki Cem Parlar, Cloe Chantereault, Lang Liu, Eric Yu, Uladzislau Rudakou, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Lior Greenbaum, Sharon Hassin‐Baer, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Roy N. Alcalay, Ziv Gan‐Or   +21 more
wiley   +1 more source

Alpha-Synuclein

, 2010
openaire   +3 more sources

Tear fluid as a novel specimen for detection of alpha-synuclein seeding activity in Parkinson's disease. [PDF]

Sci Rep
Costanzo M, Ladogana A, Sbriccoli M, Marchet F, Porreca F, Salciccia C, Equestre M, Moracci G, De Bartolo MI, Ruocco G, Carlà FC, Conte A, Fabbrini G, Belvisi D, Poleggi A.   +14 more
europepmc   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source